[Non-cirrhotic portal hypertension - The point of view of the pathologis].

Ther Umsch

Universitätsspital Basel, Institut für Medizinische Genetik und Pathologie, Pathologie, Basel.

Published: January 2020

Non-cirrhotic portal hypertension - The point of view of the pathologist Non-cirrhotic portal hypertension (NCPH) is a heterogeneous group of liver disorders leading to portal hypertension. Many disorders are associated with NCPH. Based on the site of resistance to blood flow, they are classified as pre-hepatic, hepatic, and post-hepatic. Hepatic causes are further subdivided into pre-sinusoidal, sinusoidal and post-sinusoidal. The diagnosis of idiopathic non-cirrhotic portal hypertension (INCPH) can be made if all these disorders have been excluded and consequently no clear liver disease has been identified. INCPH is clinically characterized by features of PHT, moderate to massive splenomegaly, with or without hypersplenism, and preserved liver functions. This review is focused on pathological features of INCPH, which is thought to be caused largely by parenchymal vascular obstruction. INCPH must be considered in every patient presenting with clinical signs of portal hypertension where cirrhosis appears to be absent and the cause of portal hypertension is not clear. In most instances, patients present with bleeding esophageal varices. In order to exclude severe fibrosis or cirrhosis, liver histology remains essential in the diagnosis of INCPH.

Download full-text PDF

Source
http://dx.doi.org/10.1024/0040-5930/a001106DOI Listing

Publication Analysis

Top Keywords

portal hypertension
28
non-cirrhotic portal
12
hypertension point
8
point view
8
hypertension
7
portal
6
incph
5
[non-cirrhotic portal
4
view pathologis]
4
pathologis] non-cirrhotic
4

Similar Publications

Impact of postoperative morbidity on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: a multicenter observational study.

Sci Rep

January 2025

Department of Comprehensive Surgery, Vascular Surgery, Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, 666 Shengli Road, Chongchuan District, Nantong City, 226014, Jiangsu Province, China.

The long-term impact of postoperative morbidity following laparoscopic liver resection for hepatocellular carcinoma is unclear. This study aimed to investigate whether the prognosis of hepatocellular carcinoma patients were affected by postoperative morbidity after laparoscopic liver resection. Hepatocellular carcinoma patients who underwent curative-intent laparoscopic liver resection were included.

View Article and Find Full Text PDF

Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.

Methods: In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries.

View Article and Find Full Text PDF

Unlabelled: Sinusoidal obstruction syndrome (SOS) is a distinctive and potentially fatal form of hepatic injury that mainly occurs after hematopoietic-stem cell transplantation but also due to many other conditions including drug or toxin exposure. Recently, immune checkpoint inhibitors (ICIs) have revolutionised the treatment of many solid organ malignancies. Furthermore, as their use has become more widespread, rare toxicities have emerged.

View Article and Find Full Text PDF

Portal vein recanalization transjugular intrahepatic portosystemic shunt (PVR-TIPS) is a safe and effective procedure for decompression of portal hypertension (PH). In this short case series, 2 women with chronic noncirrhotic portal vein thrombosis were treated with PVR-TIPS. Both patients hoped to conceive.

View Article and Find Full Text PDF

Purpose: This study assesses the efficacy and safety of Portal Vein Recanalization with Intrahepatic Portosystemic Shunt (PVR-TIPS) in non-cirrhotic patients with chronic portal vein occlusion (CPVO), cavernomatous transformation, and symptomatic portal hypertension (PH) and/or portal vein thrombotic progression.

Material And Methods: Medical records of 21 non-cirrhotic patients with CPVO and portal cavernoma undergoing PVR-TIPS were analyzed. Hemodynamic (intraprocedural reduction in portosystemic pressure gradient), clinical (data on gastrointestinal bleeding, abdominal pain, ascites, and presence of esophageal varices from imaging exams) and technical success (PVR-TIPS) assessed efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!